肿瘤细胞治疗研究
英文原题："Hurdles race for CAR T-cell therapy in digestive tract cancer".
消化道癌症（DTC）属于研究最多的肿瘤家族之一。
消化道肿瘤仍是全球癌症死亡的重要原因，现有治疗常受疗效不足和复发限制。CAR-T 细胞疗法在血液肿瘤中取得显著进展，但在消化道实体瘤中的应用仍面临多重挑战，包括肿瘤相关抗原异质性、正常组织表达导致的脱靶毒性、肿瘤浸润不足以及免疫抑制性微环境。本文综述CAR-T治疗消化道肿瘤的研究进展，讨论靶点选择、细胞工程和联合治疗策略，并总结该领域走向临床应用所需解决的问题。
Digestive tract cancers (DTC) belong to the most investigated family of tumors. The incidence, prevalence, and mortality rate of DTC remain high, especially for patients with pancreatic cancer. Even though immunotherapy such as immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid cancer types, ICI are still restricted to a very small group of patients and seem to be more efficacious in combination with chemotherapy. Cellular immunotherapy such as CAR T-cell therapy has entered clinical routine in hematological malignancies with outstanding results. There is growing interest on translating this kind of immunotherapy and success into patients with solid malignancies, such as DTC. This review attempts to describe the major advances in preclinical and clinical research with CAR T cells in DTC, considering the most relevant hurdles in each subtype of DTC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
